Latest / DDReg Knowledge Capsule / Regulatory Data Quality: The Hidden Risk Behind Submission & Compliance

Transcript

Regulatory Data Quality: The Hidden Risk Behind Submission & Compliance · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to the D.D. Reg Knowledge Capsule. Imagine spending $ 2
• 0:06
  Speaker 1: billion and like 10 years developing this incredible breakthrough life-saving drug.
• 0:13
  Speaker 2: Right. The clinical trials were flawless. The science is completely revolutionary.
• 0:16
  Speaker 1: Exactly. And patients are just desperately waiting for it. But
• 0:20
  Speaker 1: then right at the finish line, the entire global rollout
• 0:24
  Speaker 1: is blocked. And it's not because the drug doesn't work.
• 0:27
  Speaker 2: No, it's usually because of something completely invisible, like a
• 0:31
  Speaker 2: formatting error buried deep inside some digital database.
• 0:34
  Speaker 1: Which is just wild to think about. So today we
• 0:37
  Speaker 1: are exploring this invisible world that runs parallel to physical medicine.
• 0:42
  Speaker 1: It is a world constructed entirely of data.
• 0:46
  Speaker 2: And honestly, the sheer volume of that data is staggering.
• 0:49
  Speaker 2: It's a massive undertaking.
• 0:50
  Speaker 1: It really is. So for this deep dive, our mission
• 0:53
  Speaker 1: is to unpack this highly revealing September 2026 Insight Report
• 0:59
  Speaker 1: from DD Reg Pharma. It's all about regulatory data quality. Yeah.
• 1:03
  Speaker 2: And we're looking at why managing the labyrinth of data
• 1:06
  Speaker 2: behind a drug is becoming just as critical and frankly,
• 1:10
  Speaker 2: just as complex as the chemical engineering of the drug itself.
• 1:13
  Speaker 1: OK, let's unpack this, because to set the stage, we
• 1:16
  Speaker 1: really need to understand how the global regulatory environment is shifting.
• 1:20
  Speaker 1: It seems like we're rapidly moving away from traditional static submissions.
• 1:24
  Speaker 2: Oh, absolutely. It's a complete paradigm shift for the industry.
• 1:27
  Speaker 2: For decades, the regulatory world operated on this very document-centric model.
• 1:32
  Speaker 1: Like actual paper documents.
• 1:34
  Speaker 2: Originally, yes. If a sponsor wanted market authorization, they essentially
• 1:38
  Speaker 2: handed over literal wooden pallets stacked with physical binders.
• 1:41
  Speaker 1: Wow. Pallets of paper.
• 1:43
  Speaker 2: Right. And then eventually that evolved into flat digital files
• 1:47
  Speaker 2: like PDFs. But the whole ecosystem has evolved way beyond
• 1:50
  Speaker 2: the capacity of just static documents.
• 1:53
  Speaker 1: Because the global scale is just too big now, right?
• 1:55
  Speaker 2: Exactly. I mean, we are dealing with global pharmaceutical operations
• 1:59
  Speaker 2: where a single asset might be managed across 50 different
• 2:03
  Speaker 2: markets simultaneously.
• 2:04
  Speaker 1: And each market has its own localized rules.
• 2:07
  Speaker 2: Right. Highly specific requirements. So regulators, they're no longer satisfied
• 2:12
  Speaker 2: with just reading a summary document. They are moving toward
• 2:15
  Speaker 2: these structured, interconnected data ecosystems.
• 2:18
  Speaker 1: So they want machine-readable information. Stuff that can be queried
• 2:21
  Speaker 1: and cross-referenced in real time. Exactly.
• 2:25
  Speaker 2: But I think there's still a lingering misconception about this.
• 2:27
  Speaker 1: Oh, for sure. Even within the industry itself sometimes. Like,
• 2:31
  Speaker 1: we subconsciously imagine a drug's regulatory profile as this single
• 2:36
  Speaker 1: source of truth. You know, one cohesive master file.
• 2:40
  Speaker 2: Right. You picture just pulling up a digital folder and
• 2:43
  Speaker 2: everything is neatly organized inside it.
• 2:45
  Speaker 1: Yeah. Like, the active ingredients, the clinical trial outcomes, adverse
• 2:50
  Speaker 1: event reports, even down to the packaging dimensions, just sitting
• 2:53
  Speaker 1: in one static folder.
• 2:55
  Speaker 2: Reading through the DDREG report, it becomes glaringly obvious that the, quote,
• 2:59
  Speaker 2: single master file concept is just an utter myth.
• 3:02
  Speaker 1: It doesn't exist.
• 3:03
  Speaker 2: It is entirely a myth. And honestly, operating under that
• 3:06
  Speaker 2: assumption is incredibly dangerous from a compliance standpoint. A drug's
• 3:10
  Speaker 2: regulatory record does not exist in a vacuum.
• 3:13
  Speaker 1: Right.
• 3:14
  Speaker 2: And it certainly isn't a single file. Behind every approved therapy,
• 3:18
  Speaker 2: there is this vast decentralized web of interconnected data nodes.
• 3:22
  Speaker 1: So like your chemistry manufacturing and controls, the CMC data,
• 3:26
  Speaker 1: that's sitting in one operational silo. Exactly.
• 3:29
  Speaker 2: And then your clinical evidence and pharmacovigilance data, that's managed
• 3:33
  Speaker 2: by completely different teams.
• 3:35
  Speaker 1: And then you add in global labeling, packaging, and all
• 3:37
  Speaker 1: the constant post-approval modifications.
• 3:40
  Speaker 2: Right. And when you scale that across international borders... That
• 3:44
  Speaker 2: web stretches across diverse regional teams. They're using disparate legacy
• 3:48
  Speaker 2: IT systems, all answering to different regulatory authorities on completely
• 3:52
  Speaker 2: different timelines.
• 3:53
  Speaker 1: Okay, to help visualize the sheer chaos of that, think
• 3:56
  Speaker 1: of a drugs regulatory profile, not as a static digital binder,
• 4:01
  Speaker 1: but as a massive live Wikipedia page.
• 4:04
  Speaker 2: That's a great way to look at it.
• 4:05
  Speaker 1: Right. And it's being edited simultaneously by completely different global divisions.
• 4:10
  Speaker 1: So you could have the safety team in the EU...
• 4:13
  Speaker 1: updating an adverse event frequency based on like new real
• 4:16
  Speaker 1: world evidence.
• 4:17
  Speaker 2: While at the exact same moment, the manufacturing team in
• 4:20
  Speaker 2: Asia is tweaking a sourcing detail for an excipient.
• 4:23
  Speaker 1: Yeah. And then the commercial team in the U.S. is
• 4:26
  Speaker 1: altering the formatting of the packaging label to meet some
• 4:28
  Speaker 1: new FDA guidance. It's all happening at once. But wait,
• 4:33
  Speaker 1: if this information is so critical, shouldn't it be easy
• 4:35
  Speaker 1: to just keep it all in one master file?
• 4:37
  Speaker 2: Well, what's fascinating here is that regulators are actually acutely
• 4:41
  Speaker 2: aware of this simultaneous multi-regional editing. And they are actively
• 4:46
  Speaker 2: designing their frameworks to control it.
• 4:48
  Speaker 1: Like the European Medicines Agency, right?
• 4:50
  Speaker 2: Exactly.
• 4:50
  Speaker 1: The EMA.
• 4:51
  Speaker 2: Look at their data quality framework. They are explicitly shifting
• 4:55
  Speaker 2: the burden of proof. The framework dictates that regulators shouldn't
• 4:59
  Speaker 2: have to hunt through a 500-page PDF to make sure
• 5:01
  Speaker 2: the safety profile matches the label.
• 5:04
  Speaker 1: Right. They shouldn't be the ones doing the proofreading.
• 5:05
  Speaker 2: No, they expect the sponsor to submit an interconnected, structured
• 5:09
  Speaker 2: data record where all those elements are digitally linked and
• 5:12
  Speaker 2: flawlessly consistent.
• 5:14
  Speaker 1: So the expectation is no longer just, you know, avoiding typos.
• 5:17
  Speaker 2: Not at all. The expectation is absolute, demonstrable data integrity
• 5:21
  Speaker 2: across every single node of that global Wikipedia page.
• 5:25
  Speaker 1: Okay, but I have to push back a little bit
• 5:26
  Speaker 1: on the complexity argument here. Because, I mean, we've had advanced...
• 5:30
  Speaker 1: regulatory information management systems, RIMS, for years now.
• 5:34
  Speaker 2: We have, yes.
• 5:34
  Speaker 1: And these enterprise-level pharma companies, they've spent tens of millions
• 5:39
  Speaker 1: of dollars rolling out centralized software to manage this exact problem.
• 5:42
  Speaker 2: They certainly have.
• 5:44
  Speaker 1: So if the software already exists and the industry knows
• 5:47
  Speaker 1: this data is critical, why is this still a widespread crisis?
• 5:50
  Speaker 1: But wait, these are massive, highly regulated pharmaceutical companies. Are
• 5:54
  Speaker 1: you telling me they're still struggling with manual data entry
• 5:57
  Speaker 1: and duplicate records like a messy shared spreadsheet?
• 6:00
  Speaker 2: This raises an important question. And honestly, it highlights one
• 6:04
  Speaker 2: of the most dangerous blind spots in the industry right now.
• 6:06
  Speaker 1: Which of what?
• 6:07
  Speaker 2: Conflating technology with governance. Yes, these are sophisticated multi-billion dollar organizations.
• 6:13
  Speaker 2: And you're right. They invest heavily in enterprise RIMS platforms
• 6:16
  Speaker 2: to act as that central hub.
• 6:18
  Speaker 1: Right. The software is top tier.
• 6:19
  Speaker 2: But here is the messy operational reality. A state-of-the-art software
• 6:24
  Speaker 2: platform is completely defenseless against bad data if you lack
• 6:27
  Speaker 2: the governance to control what actually goes into it.
• 6:30
  Speaker 1: Ah, okay. So it's like building a fully automated billion-dollar
• 6:34
  Speaker 1: manufacturing facility but feeding it contaminated raw materials.
• 6:38
  Speaker 2: That is the perfect analogy.
• 6:40
  Speaker 1: Because the automated system won't fix the materials. It will
• 6:43
  Speaker 1: just perfectly and efficiently distribute that contamination across your entire
• 6:47
  Speaker 1: global supply chain. Exactly.
• 6:50
  Speaker 2: The RIMS will simply codify and distribute your errors at
• 6:53
  Speaker 2: lightning speed. The DDREG report points out that poor regulatory
• 6:57
  Speaker 2: data doesn't usually stem from a single catastrophic failure.
• 7:01
  Speaker 1: It's more insidious than that.
• 7:03
  Speaker 2: It is. It's the result of compounding friction. It starts
• 7:07
  Speaker 2: with those disconnected legacy systems. So perhaps a company acquires
• 7:11
  Speaker 2: another biotech firm.
• 7:12
  Speaker 1: Oh, right. Mergers and acquisitions. Exactly.
• 7:14
  Speaker 2: Exactly. And now they have one database for document management,
• 7:18
  Speaker 2: an entirely separate legacy platform for safety, and some localized
• 7:23
  Speaker 2: SharePoint architecture for manufacturing.
• 7:25
  Speaker 1: And because these systems don't talk to each other, human
• 7:27
  Speaker 1: beings are forced to manually transcribe data between them. Yes.
• 7:31
  Speaker 2: And the moment you introduce manual data entry into a
• 7:33
  Speaker 2: process that spans thousands of data points.
• 7:37
  Speaker 1: Human error is basically a mathematical certainty. Exactly.
• 7:40
  Speaker 2: Let's trace the mechanics of that. Say the manufacturing team
• 7:43
  Speaker 2: validates a shelf life extension for a product, moving it
• 7:46
  Speaker 2: from 24 months to 36 months.
• 7:49
  Speaker 1: Okay, good news for the drug.
• 7:50
  Speaker 2: So they update their CMC database. Right. But because the
• 7:54
  Speaker 2: systems don't talk, the local affiliate in some mid-sized market
• 7:57
  Speaker 2: relies on a manual email notification to update their local
• 8:00
  Speaker 2: labeling system.
• 8:01
  Speaker 1: Oh no. Until the email gets missed, or maybe someone
• 8:04
  Speaker 1: leaves the company. Exactly.
• 8:06
  Speaker 2: And suddenly the official label in that country still says
• 8:08
  Speaker 2: 24 months, while the approved manufacturing data says 36.
• 8:12
  Speaker 1: So now you have a severe discrepancy between the approved
• 8:15
  Speaker 1: data and the public facing product information. That's a massive
• 8:19
  Speaker 1: compliance risk. It is.
• 8:21
  Speaker 2: And the second major driver of this bad data beyond
• 8:23
  Speaker 2: just manual entry is a pervasive lack of clear ownership.
• 8:27
  Speaker 1: What do you mean by that?
• 8:28
  Speaker 2: Well, when regulatory affairs, quality assurance, clinical and commercial teams
• 8:32
  Speaker 2: are all touching different facets of the product record, the
• 8:35
  Speaker 2: responsibility for maintaining the definitive source of truth becomes highly ambiguous. Right.
• 8:41
  Speaker 1: Everyone thinks it's someone else's job to update the master record.
• 8:44
  Speaker 2: Exactly. And when that ambiguity hits a marketing authorization application,
• 8:49
  Speaker 2: an MAA, the financial and public health impacts are severe.
• 8:53
  Speaker 1: Because the regulators are using sophisticated tools themselves now. They
• 8:56
  Speaker 1: aren't just skimming these submissions anymore.
• 8:58
  Speaker 2: No, they are scanning them. And if there is a
• 9:00
  Speaker 2: misalignment between, say, the clinical module and the proposed labeling
• 9:05
  Speaker 2: module in an MAA, they will flag it immediately.
• 9:08
  Speaker 1: Which leads to a whole cascade of operational nightmares. Like
• 9:11
  Speaker 1: a flagged inconsistency results in a request for information, right?
• 9:15
  Speaker 1: An RTQ from the authority.
• 9:17
  Speaker 2: Yes. And the review clock completely stops. The sponsor has
• 9:21
  Speaker 2: to scramble to perform this massive retrospective data sweep just
• 9:25
  Speaker 2: to find out where the disconnect happened.
• 9:27
  Speaker 1: And that delays the whole approval process by months. I mean,
• 9:31
  Speaker 1: in the pharma industry, a three-month delay in market access
• 9:33
  Speaker 1: doesn't just mean a huge hit to projected revenue.
• 9:36
  Speaker 2: No, it means a potentially life-altering delay for patient populations
• 9:40
  Speaker 2: awaiting that therapy.
• 9:41
  Speaker 1: Plus, it fundamentally erodes the regulator's confidence in the sponsor. Absolutely.
• 9:45
  Speaker 2: If a regulator finds a careless data discrepancy in the
• 9:48
  Speaker 2: labeling module, they are naturally going to scrutinize the critical
• 9:51
  Speaker 2: safety and efficacy data with way more skepticism.
• 9:54
  Speaker 1: The stakes are just astronomical just to get through the door. But,
• 9:58
  Speaker 1: you know, it strikes me that approval is essentially just
• 10:01
  Speaker 1: the end of the prologue.
• 10:03
  Speaker 2: That's a very good way to frame it.
• 10:04
  Speaker 1: Right? Because the drug doesn't get frozen in amber once
• 10:08
  Speaker 1: it hits the market. Science evolves. Manufacturing processes are optimized.
• 10:13
  Speaker 1: New indications are discovered. Real-world safety signals emerge.
• 10:17
  Speaker 2: Right.
• 10:18
  Speaker 1: So... What does this all mean for the business itself?
• 10:21
  Speaker 1: Maintaining this data ecosystem must be a perpetual burden.
• 10:24
  Speaker 2: It is a never-ending cycle. It's formally known as post-approval
• 10:28
  Speaker 2: lifecycle management. And the D.D. Reg report really emphasizes that
• 10:33
  Speaker 2: regulatory obligations expand significantly post-launch.
• 10:37
  Speaker 1: Because you're dealing with a constant stream of variations, right?
• 10:40
  Speaker 2: Exactly. You have type I.A. and type I.B. variations for
• 10:44
  Speaker 2: minor changes. Type two variations for major clinical or manufacturing overhauls.
• 10:50
  Speaker 1: Not to mention license renewals and geographic expansions.
• 10:54
  Speaker 2: Right. The product's regulatory record is a living, breathing entity,
• 10:58
  Speaker 2: and it must remain perfectly synchronized across every market it
• 11:02
  Speaker 2: inhabits for the entirety of its commercial lifespan.
• 11:05
  Speaker 1: Which means if a company has poor data governance, that
• 11:08
  Speaker 1: legacy data becomes this massive, invisible operational tax.
• 11:12
  Speaker 2: That is exactly what it becomes.
• 11:14
  Speaker 1: Let's say a company wants to take a successful oncology
• 11:17
  Speaker 1: drug approved in the EU and launch it in Latin America. Okay.
• 11:22
  Speaker 1: If their baseline regulatory data is just a mess of
• 11:25
  Speaker 1: duplicated records and conflicting version histories, they can't just confidently
• 11:29
  Speaker 1: hit export, right?
• 11:30
  Speaker 2: No, they absolutely cannot.
• 11:31
  Speaker 1: They would have to spend like six months auditing their
• 11:34
  Speaker 1: own internal systems just to figure out which version of
• 11:37
  Speaker 1: the product dossier is the definitive truth.
• 11:41
  Speaker 2: All of that? Before they can even begin the new
• 11:44
  Speaker 2: regional submission.
• 11:45
  Speaker 1: So approval isn't the finish line at all. It's the
• 11:49
  Speaker 1: starting gun for data maintenance.
• 11:51
  Speaker 2: If we connect this to the bigger picture, regulatory data
• 11:54
  Speaker 2: quality is not merely a localized compliance hurdle. It is
• 11:57
  Speaker 2: a fundamental business control issue.
• 12:00
  Speaker 1: Because this hidden operational burden translates directly to the bottom line. Yes.
• 12:05
  Speaker 2: This invisible tax drains resources, artificially inflates regulatory review cycles,
• 12:11
  Speaker 2: and completely throttles market agility.
• 12:13
  Speaker 1: But on the flip side, pristine, high-quality data creates immense
• 12:18
  Speaker 1: strategic leverage.
• 12:20
  Speaker 2: Exactly. It acts as an operational shield. When your data
• 12:23
  Speaker 2: is structured, standardized, and perfectly governed, you can execute market
• 12:28
  Speaker 2: expansions with precision.
• 12:29
  Speaker 1: You can respond to regulator inquiries instantly.
• 12:32
  Speaker 2: Right, and drastically reduce the overhead costs associated with all
• 12:35
  Speaker 2: that manual submission rework.
• 12:38
  Speaker 1: Okay, so the stakes are super clear. the complexities are vast.
• 12:42
  Speaker 1: And relying on static PDFs and manual transcription is obviously
• 12:46
  Speaker 1: a recipe for disaster.
• 12:47
  Speaker 2: A total disaster, yeah.
• 12:48
  Speaker 1: The industry clearly needs a systemic overhaul. So let's dig
• 12:52
  Speaker 1: into the actual mechanics of how pharma is solving this crisis.
• 12:56
  Speaker 1: Because the report highlights massive structural initiatives like IDMP and
• 13:00
  Speaker 1: the EU EPI.
• 13:02
  Speaker 2: Yes, those are the major game changers right now.
• 13:05
  Speaker 1: Let's break down how these actually function on a technical level.
• 13:08
  Speaker 1: Because They really seem to be the primary mechanisms forcing
• 13:11
  Speaker 1: this shift from documents to data.
• 13:13
  Speaker 2: They are the tip of the spear. So IDMP, which
• 13:17
  Speaker 2: stands for the Identification of Medicinal Products, is an internationally
• 13:21
  Speaker 2: mandated set of standards.
• 13:23
  Speaker 1: But it's not just a set of rules, is it?
• 13:25
  Speaker 2: No, it is essentially a completely new structured language. It's
• 13:29
  Speaker 2: designed to uniquely identify every single element of a medicinal product.
• 13:34
  Speaker 1: So it breaks down a drug into specific data attributes. Exactly. Substances,
• 13:38
  Speaker 1: product characteristics, organizational details, and referential vocabularies. It's often referred
• 13:44
  Speaker 1: to as SPOR data.
• 13:46
  Speaker 2: Got it.
• 13:47
  Speaker 1: And then you have the EUEPI, the Electronic Product Information Initiative.
• 13:51
  Speaker 2: Right.
• 13:52
  Speaker 1: And to understand the mechanism here, EPI isn't just taking
• 13:56
  Speaker 1: a paper label and scanning it into a computer.
• 13:59
  Speaker 2: Not at all. Right.
• 14:00
  Speaker 1: It's fundamentally altering the architecture of the information. Right.
• 14:03
  Speaker 2: Instead of a flat visual document where a human has
• 14:06
  Speaker 2: to read a paragraph to find the dosage, EPI utilizes
• 14:09
  Speaker 2: XML schemas and structured metadata.
• 14:12
  Speaker 1: Exactly.
• 14:12
  Speaker 2: Every specific piece of information, the contraindications, the excipients, the
• 14:18
  Speaker 2: specific pediatric dosing, it's all individually tagged with machine-readable code.
• 14:23
  Speaker 1: So a computer system can instantly cross-reference that XML tag
• 14:27
  Speaker 1: against the global database. And it can flag any discrepancies
• 14:31
  Speaker 1: without a human ever having to read the text. Precisely.
• 14:34
  Speaker 2: You are transitioning from unstructured narrative text into highly structured,
• 14:38
  Speaker 2: interoperable data fields.
• 14:40
  Speaker 1: But implementing this must require a monumental organizational shift.
• 14:44
  Speaker 2: It does, which is why D.D. Reg outlines a very
• 14:47
  Speaker 2: specific strategic approach in their Insight Report. They advocate for
• 14:51
  Speaker 2: a five-step holistic framework that addresses people, processes, technology, and governance.
• 14:56
  Speaker 1: Here's where it gets really interesting to me. I want
• 14:59
  Speaker 1: to zoom in on the cultural aspect of this. specifically
• 15:02
  Speaker 1: the first critical component of their framework, data ownership.
• 15:06
  Speaker 2: Okay, yeah.
• 15:08
  Speaker 1: Because on paper, assigning ownership just sounds like standard corporate management, right?
• 15:12
  Speaker 2: It does sound simple on paper.
• 15:14
  Speaker 1: But earlier we discussed how a single drug's life cycle
• 15:17
  Speaker 1: spans clinical scientists, safety officers, and commercial directors. How does
• 15:21
  Speaker 1: a company actually enforce ownership across all those diverse teams?
• 15:25
  Speaker 2: Well, it requires moving from a document mindset to a
• 15:28
  Speaker 2: data mindset. And that is arguably the most difficult hurdle
• 15:32
  Speaker 2: in the entire transition.
• 15:33
  Speaker 1: I can imagine. Can you explain the actual day-to-day friction
• 15:37
  Speaker 1: of forcing that paradigm shift within like a legacy pharma company? Sure.
• 15:41
  Speaker 2: So in a traditional document mindset, a clinical scientist feels
• 15:45
  Speaker 2: ownership over their 200-page clinical study report.
• 15:48
  Speaker 1: They authored it.
• 15:48
  Speaker 2: They authored it, they reviewed it, and they signed off
• 15:51
  Speaker 2: on it as a cohesive document. But in a data mindset...
• 15:55
  Speaker 2: You have to convince that exact same scientist that they
• 15:57
  Speaker 2: no longer own the report itself.
• 16:00
  Speaker 1: Wait, really? Then what do they own?
• 16:03
  Speaker 2: They own the specific data attributes, like the statistical frequency
• 16:07
  Speaker 2: of a particular adverse event.
• 16:09
  Speaker 1: Oh, wow.
• 16:10
  Speaker 2: Yeah, that single validated data point becomes the single source
• 16:14
  Speaker 2: of truth. And then that point is dynamically pulled into
• 16:17
  Speaker 2: the clinical study report, the safety update, and the eventual
• 16:20
  Speaker 2: EPI XML file.
• 16:22
  Speaker 1: So you are... breaking down the historical silos. You are
• 16:26
  Speaker 1: essentially telling highly specialized professionals, you don't own the piece
• 16:30
  Speaker 1: of paper anymore. You own this specific fragment of code.
• 16:33
  Speaker 2: Exactly. And you are responsible for its accuracy no matter
• 16:37
  Speaker 2: where it automatically propagates across the globe.
• 16:40
  Speaker 1: That is a massive mental shift. It is.
• 16:44
  Speaker 2: And that requires cross-functional governance structures that simply didn't exist
• 16:48
  Speaker 2: in pharma 10 years ago.
• 16:49
  Speaker 1: Okay. So once you establish that ownership, what's next?
• 16:52
  Speaker 2: You move to the second step of the framework, data standardization.
• 16:57
  Speaker 2: Because you are now dealing with attributes instead of documents,
• 17:00
  Speaker 2: everyone globally must use the exact same controlled vocabularies and ontologies.
• 17:05
  Speaker 1: So a manufacturing facility in Tokyo and a clinical trial
• 17:09
  Speaker 1: site in London must use the identical standardized code to
• 17:13
  Speaker 1: describe the same chemical substance.
• 17:15
  Speaker 2: Exactly. Otherwise, the interoperability completely fails.
• 17:19
  Speaker 1: But even with ownership assigned and vocabulary standardized, you still
• 17:24
  Speaker 1: have human beings interacting with the system, right? So how
• 17:27
  Speaker 1: does the framework account for inevitable human error?
• 17:31
  Speaker 2: That is where the third step comes in. Data validation controls.
• 17:35
  Speaker 2: You don't wait for a regulator to find the error
• 17:37
  Speaker 2: during an MAA review. You implement automated systemic checkpoints within
• 17:42
  Speaker 2: your data architecture.
• 17:43
  Speaker 1: Oh, so these controls are designed to constantly scan for
• 17:47
  Speaker 1: missing attributes.
• 17:47
  Speaker 2: Right. they flag duplicate entries, and they identify conflicting data
• 17:52
  Speaker 2: logic in real time.
• 17:54
  Speaker 1: And then only when the data is validated does it
• 17:56
  Speaker 1: flow into the fourth component.
• 17:58
  Speaker 2: Yes, the integrated regulatory systems. This is where your sophisticated
• 18:03
  Speaker 2: RIMS platform finally does its job. It acts as the centralized,
• 18:06
  Speaker 2: authoritative repository for all this validated, structured information.
• 18:11
  Speaker 1: And the fifth and final piece of that framework is
• 18:13
  Speaker 1: continuous monitoring. Exactly.
• 18:15
  Speaker 2: Which makes perfect sense based on our Earlier discussion of
• 18:19
  Speaker 2: lifecycle management.
• 18:20
  Speaker 1: Right, because data quality isn't just a box you check
• 18:22
  Speaker 1: before a submission. It's an ongoing operational metric that has
• 18:26
  Speaker 1: to be monitored for the entire life of the asset.
• 18:28
  Speaker 2: Absolutely. And this is exactly where DDRig bridges the gap
• 18:32
  Speaker 2: between theory and execution for these companies. They don't just
• 18:35
  Speaker 2: provide the strategic roadmap.
• 18:37
  Speaker 1: They supply the technical architecture to make it a reality.
• 18:40
  Speaker 1: They do.
• 18:41
  Speaker 2: Implementing this level of rigorous data governance is incredibly daunting
• 18:45
  Speaker 2: for organizations bogged down by legacy systems. So DD-Reg provides
• 18:49
  Speaker 2: comprehensive regulatory data quality assessments to map out the existing
• 18:53
  Speaker 2: friction points.
• 18:54
  Speaker 1: And they help engineer those cross-functional governance models required to
• 18:58
  Speaker 1: actually enforce the data ownership.
• 19:00
  Speaker 2: Yes. But they also bring highly specialized digital tools to
• 19:03
  Speaker 2: the table to handle the sheer volume of this transition.
• 19:06
  Speaker 2: For instance, they utilize Vitalik LC.
• 19:09
  Speaker 1: Which is their lifecycle tracking software, right?
• 19:11
  Speaker 2: Right. It's a dedicated tracking software for regulatory lifecycle management.
• 19:15
  Speaker 2: It gives global teams live, transparent visibility into the status
• 19:19
  Speaker 2: of their product data across all international markets.
• 19:21
  Speaker 1: So it essentially eliminates those blind spots we discussed earlier. Exactly.
• 19:25
  Speaker 1: And then there is the truly frontier technology they deploy,
• 19:29
  Speaker 1: which is Vitalik Regintel. Because the global regulatory landscape isn't static.
• 19:35
  Speaker 1: Guidelines change constantly.
• 19:36
  Speaker 2: All the time. And Vitalik Regintel utilizes AI-powered regulatory intelligence
• 19:41
  Speaker 2: to manage that.
• 19:42
  Speaker 1: Right. It uses natural language processing to continuously scan and
• 19:46
  Speaker 1: parse updates from over 120 global regulatory agencies.
• 19:50
  Speaker 2: It reads the changing compliance landscapes and translates them into
• 19:53
  Speaker 2: actionable data.
• 19:55
  Speaker 1: Allowing a company to proactively adapt their strategy before a
• 19:58
  Speaker 1: new guideline causes a compliance failure. That is wild.
• 20:01
  Speaker 2: It is a remarkable capability. It takes the external chaos
• 20:04
  Speaker 2: of global regulatory changes and integrates it smoothly into an
• 20:08
  Speaker 2: organization's internal data governance strategy.
• 20:11
  Speaker 1: Which really brings us full circle to the core thesis
• 20:14
  Speaker 1: of this entire deep dive. A successful pharmaceutical product today
• 20:18
  Speaker 1: is no longer defined solely by flawless science.
• 20:21
  Speaker 2: No, it is equally defined by flawless data.
• 20:24
  Speaker 1: We have definitively moved past the era where data management
• 20:28
  Speaker 1: was viewed as just like a tedious administrative chore to
• 20:31
  Speaker 1: avoid typos on a label.
• 20:33
  Speaker 2: Regulatory data quality is the active, continuous process of engineering trust.
• 20:38
  Speaker 2: It is the structural foundation that ensures compliance, accelerates market access,
• 20:42
  Speaker 2: and ultimately guarantees that the physical drug reaches the patient safely.
• 20:46
  Speaker 1: And that is the crucial takeaway. Without a highly structured,
• 20:50
  Speaker 1: fiercely governed data ecosystem, the entire mechanism of global healthcare
• 20:54
  Speaker 1: delivery just grinds to a halt.
• 20:57
  Speaker 2: The data really is the circulatory system of the pharmaceutical industry.
• 21:01
  Speaker 1: It is a profound realization. So to you listening right now,
• 21:06
  Speaker 1: the next time you pick up a bottle of medication,
• 21:08
  Speaker 1: the next time you glance at the warning label or
• 21:11
  Speaker 1: read those highly specific dosage instructions, I want you to pause.
• 21:15
  Speaker 2: Yeah. Think about what it took to get that text there.
• 21:18
  Speaker 1: Exactly. Think about the massive, invisible global data ecosystem that
• 21:23
  Speaker 1: is actively working around the clock to keep that single
• 21:26
  Speaker 1: sentence accurate. Think about the standardization, the automated validation controls,
• 21:32
  Speaker 1: and the cross-functional governance required to ensure that specific text
• 21:36
  Speaker 1: is flawlessly aligned with the underlying clinical science.
• 21:40
  Speaker 2: It is a monumental achievement of human coordination.
• 21:43
  Speaker 1: It really is data engineering at its finest. And I
• 21:46
  Speaker 1: will leave you with this final thought to explore on
• 21:49
  Speaker 1: your own. As the industry accelerates its shift entirely away
• 21:53
  Speaker 1: from static documents into these highly structured XML-driven data ecosystems,
• 21:59
  Speaker 1: And with tools like Vitalik Regintel already introducing AI into
• 22:02
  Speaker 1: the compliance workflow, we are standing on the edge of
• 22:05
  Speaker 1: an incredible new frontier.
• 22:07
  Speaker 2: We truly are.
• 22:09
  Speaker 1: If our data architectures become perfectly structured and machine-readable, how
• 22:13
  Speaker 1: long until AI systems can automatically detect subtle, emergent safety
• 22:18
  Speaker 1: signals hidden deep within the real-world data? Or instantly flag
• 22:22
  Speaker 1: a global compliance risk before a human regulator even knows
• 22:25
  Speaker 1: to ask the question? It makes you wonder. As the
• 22:29
  Speaker 1: regulatory framework becomes entirely digital, how long until the system
• 22:33
  Speaker 1: is intelligent enough to not just store the data, but
• 22:36
  Speaker 1: actively protect the patient?